Deals

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal
BioMarin PharmaceuticalNASDAQ: BMRN

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that it has entered into an exclusive worldwide (excluding Korea) license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to co‑develop and…

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Eli LillyNYSE: LLY

Lilly Nears $1 Billion Deal for Ventyx’s IBD Pipeline

Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal
Eli LillyNimbus Therapeutics

Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal

Mabwell's SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson's Trials
ABLi TherapeuticsMabwell Bioscience

Mabwell’s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson’s Trials

Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases
Auto-immuneEarendil Labs

Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases

Show More